Dr. Beck and Dr. Steer Reply
Dr. Beck and Dr. Steer Reply
复制标题
贝克博士和斯蒂尔博士回复
DOI:
10.1176/ajp.147.11.1577-a
复制
发表时间:
1990
影响因子:
17.7
通讯作者:
R. Steer
中科院分区:
文献类型:
--
作者:
A. Beck;R. Steer
Am J Psychiatry 147: 1 1, November 1990 1577 daunting question: what are the appropriate algorithms for making clinical decisions in psychopharmacologic treatment of the elderly? The issue of carbamazepine serum level and its variability in the presence of MAOIs is only one of a number of questions regarding efficacy and toxicity in the authors’ case report. Is carbamazepine an appropriate first-line treatment for poststroke depression? Should three psychoactive pharmaceuticals be used during the first step of a treatment strategy for this disorder(2)? Is the carbamazepine and lithium combination safe (3)? Is the blood level of canbamaze-pine the only relevant risk factor with respect to the pharmacodynamic impact of canbamazepine and phenelzine or other MAOIs in combination(ie, what are the risks of de-linium, postural hypotension, and hypertensive crisis, in pan-ticulan)? Does canbamazepine, with its tnicyclic structure not dissimilar to that of tnicyclic antidepressants, adversely po-tentiate the risk of hypertensive crises when it is used con-comitantly with MAOIs? Moreover, was the combination of carbamazepine and phenelzine in this case necessary, as phenelzine alone or no treatment might have worked equally well?